US Broker Ratings

SI-BONE, Inc. (SIBN)

⚠️ No article content returned.

..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with a Potential 98% Upside

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is making waves in the healthcare sector, specifically within the biotechnology industry, with its robust pipeline of therapies targeting central nervous system (CNS) disorders...

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: High Revenue Growth Propels Interest Despite Challenging Valuation Metrics

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a burgeoning player in the biotechnology sector, has been capturing attention with its impressive revenue growth figures despite the complex dynamics of its financial..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with 43% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is carving a niche in the biotechnology sector with its pioneering approach to cancer treatment. Specializing in the development of small molecule inhibitors, the company..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Potential Upside of Over 100% with Strong Revenue Growth

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a commercial-stage biopharmaceutical company based in Chicago, Illinois, has been making waves in the healthcare sector. Focused on developing therapies for chronic endocrine and..

KalVista Pharmaceuticals (KALV) Stock Analysis: 95.63% Potential Upside Beckons Investors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is making waves in the biotechnology sector with its promising pipeline of drug therapies aimed at addressing diseases with unmet medical needs. With a market..

uniQure N.V. (QURE) Stock Analysis: Exploring a 124% Upside Potential in the Biotechnology Sector

Investors with a keen eye on the biotechnology sector may want to turn their attention to uniQure N.V. (NASDAQ: QURE), a Netherlands-based firm making waves with its innovative approach to..

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a 164% Potential Upside

Investors with an eye on the biotechnology sector may find AbCellera Biologics Inc. (NASDAQ: ABCL) an intriguing prospect, especially given the stock’s potential upside of 164.17%. This Canadian biotech firm,..

Neuropace, Inc. (NPCE) Stock Analysis: Insights into a 40% Potential Upside in the Medical Device Market

Neuropace, Inc. (NPCE), a key player in the medical devices sector focusing on innovative solutions for drug-resistant focal epilepsy, is capturing attention with its impressive market potential. With a market..

Valneva SE (VALN) Stock Analysis: A 25% Upside Potential in the Biotechnology Sector

Valneva SE (NASDAQ: VALN), a French biotechnology firm specializing in the development and commercialization of vaccines for infectious diseases, presents a compelling case for investors seeking opportunities in the healthcare..

ArriVent BioPharma, Inc. (AVBP) Investor Outlook: Analyzing a Potential 67.83% Upside in a Promising Biotech

ArriVent BioPharma, Inc. (NASDAQ: AVBP) stands out in the healthcare sector as a beacon of innovation within the biotechnology industry. With a market capitalization of $1.07 billion, ArriVent is carving..

Kura Oncology, Inc. (KURA) Stock Analysis: Unveiling a 266% Potential Upside in the Biotech Frontier

For investors with an eye on the biotechnology sector, Kura Oncology, Inc. (NASDAQ: KURA) presents an intriguing prospect. With its focus on developing innovative cancer treatments, Kura stands at a..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a Potential 96.78% Upside in Biotech Innovation

Intellia Therapeutics, Inc. (NASDAQ: NTLA) stands at the forefront of the biotechnology industry with its pioneering work in genome editing treatments. As a clinical-stage company, Intellia is focused on developing..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a 333.89% Potential Upside in the Biotechnology Sector

Investors seeking opportunities in the biotechnology sector might want to consider LENZ Therapeutics, Inc. (NASDAQ: LENZ), a company making strides in the field of vision-improving therapies. With a market capitalization..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 100% Potential Upside in Healthcare Tech

Simulations Plus, Inc. (NASDAQ: SLP), a key player in the Healthcare sector, specializes in developing cutting-edge drug discovery and development software. The company is renowned for leveraging artificial intelligence and..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech Prospect with Nearly 92% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI) stands out in the biotechnology sector with a promising outlook for investors seeking growth opportunities in the healthcare industry. With a market capitalization of $1.44..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 373% Upside in the Biotech Sector

Anavex Life Sciences Corp. (NASDAQ: AVXL), a prominent player in the biotechnology sector, has been capturing investor attention with its ambitious pipeline geared towards tackling neurodegenerative diseases. With a current..

GH Research PLC (GHRS) Stock Analysis: Potential Upside of 152.90% Amid Strong Buy Ratings

Ireland-based GH Research PLC (NASDAQ: GHRS) is a promising player in the biotechnology industry, specializing in the development of innovative treatments for depression. With a market capitalization nearing the $1..

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Market with 47% Revenue Growth

Cronos Group Inc. (NASDAQ: CRON) stands as a notable player in the burgeoning cannabis industry, with its headquarters rooted in Stayner, Canada. As a company engaged in the cultivation, production,..

InMode Ltd. (INMD) Stock Analysis: 31.66% Potential Upside in the Healthcare Sector

InMode Ltd. (NASDAQ: INMD), a prominent player in the healthcare sector, particularly within the medical devices industry, presents an intriguing investment opportunity for those with an eye on the future..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds